ALKS vs SRPT · P/E 14, rev $1.56B vs rev $1.90B
Alkermes Plc (ALKS) versus Sarepta Therapeutics Inc (SRPT) — a side-by-side from cached financials, not a winner call.
Alkermes Plc (ALKS) is a drug manufacturers - specialty & generic company listed on US.
Sarepta Therapeutics Inc (SRPT) is a biotechnology company listed on US.
Latest reported ALKS revenue for 2024-12-31 was $1.56B. Net income was $367.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. ALKS currently screens at market cap $4.78B and trailing P/E 13.8.
Latest reported SRPT revenue for 2024-12-31 was $1.90B. Net income was $235.2M. Revenue was up 53.0% from 2023-12-31 to 2024-12-31. SRPT currently screens at market cap $2.34B.
ALKS currently screens at market cap $4.78B and trailing P/E 13.8. SRPT currently screens at market cap $2.34B.
Not investment advice. Open the ALKS and SRPT stock pages for the full models.
Not investment advice.